Smoking cessation · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anxiety · people at high risk of or withcardiovascular disease
1 finding from 1 review
Depression, change from baseline · people at high risk of or withcardiovascular disease
1 finding from 1 review
Perceived stress, change from baseline · people at high risk of or withcardiovascular disease
1 finding from 1 review
General well‐being · people at high risk of or withcardiovascular disease
1 finding from 1 review
Adverse events · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Smoking cessation · people at high risk of or withcardiovascular disease
Mindfulness‐based interventions (MBIs) showed no clear difference in smoking cessation compared with active comparators (low certainty).
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with active control (moderate certainty).
1 finding from 1 review
Withdrew due to intolerance ( · preventing the progression of CKD
Metformin showed no clear difference in withdrew due to intolerance ( compared with active control (moderate certainty).
1 finding from 1 review
Dosing and tolerance ( · preventing the progression of CKD
1 finding from 1 review
Kidney failure · preventing the progression of CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
UACR (% change) ( · preventing the progression of CKD
1 finding from 1 review
Change in eGFR · preventing the progression of CKD
1 finding from 1 review
All‐cause death ( · preventing the progression of CKD
Metformin showed no clear difference in all‐cause death ( compared with active control (low certainty).
1 finding from 1 review
Word retrieval · adults with primary progressive aphasia (PPA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall language abilities · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Cognitive function · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Quality of life · adults with primary progressive aphasia (PPA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Clinical remission · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes clinical remission (14 days) compared with placebo (very low certainty).
1 finding from 1 review